siRNA silencing efficacy prediction using the RNA string kernel

Author(s):  
Shibin Qiu ◽  
Terran Lane
BMC Genomics ◽  
2018 ◽  
Vol 19 (S7) ◽  
Author(s):  
Ye Han ◽  
Fei He ◽  
Yongbing Chen ◽  
Yuanning Liu ◽  
Helong Yu

2011 ◽  
Vol 18 (10) ◽  
pp. 707-716 ◽  
Author(s):  
S-T Chou ◽  
Q Leng ◽  
P Scaria ◽  
M Woodle ◽  
A J Mixson
Keyword(s):  

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1995
Author(s):  
Salvatore Nicola Bertuccio ◽  
Laura Anselmi ◽  
Riccardo Masetti ◽  
Annalisa Lonetti ◽  
Sara Cerasi ◽  
...  

Despite improvements in therapeutic protocols and in risk stratification, acute myeloid leukemia (AML) remains the leading cause of childhood leukemic mortality. Indeed, the overall survival accounts for ~70% but still ~30% of pediatric patients experience relapse, with poor response to conventional chemotherapy. Thus, there is an urgent need to improve diagnosis and treatment efficacy prediction in the context of this disease. Nowadays, in the era of high throughput techniques, AML has emerged as an extremely heterogeneous disease from a genetic point of view. Different subclones characterized by specific molecular profiles display different degrees of susceptibility to conventional treatments. In this review, we describe in detail this genetic heterogeneity of pediatric AML and how it is linked to relapse in terms of clonal evolution. We highlight some innovative tools to characterize minor subclones that could help to enhance diagnosis and a preclinical model suitable for drugs screening. The final ambition of research is represented by targeted therapy, which could improve the prognosis of pediatric AML patients, as well as to limit the side toxicity of current treatments.


2017 ◽  
Vol 14 (5) ◽  
pp. 1706-1717 ◽  
Author(s):  
Anna Lechanteur ◽  
Tania Furst ◽  
Brigitte Evrard ◽  
Philippe Delvenne ◽  
Géraldine Piel ◽  
...  

2013 ◽  
Vol 54 (1) ◽  
pp. 494 ◽  
Author(s):  
Edwin H. A. Allen ◽  
Sarah D. Atkinson ◽  
Haihui Liao ◽  
Jonathan E. Moore ◽  
Deena M. Leslie Pedrioli ◽  
...  

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Jingjing Zhang ◽  
Jun Xu ◽  
Yonghong Dong ◽  
Bo Huang

In view of the high incidence of gastric cancer and the functions of hypoxia-inducible factor 1α (HIF-1α), our study aimed to investigate the functionality of HIF-1α in gastric cancer, and to explore the diagnostic and prognostic values of HIF-1α for this disease. Expression of HIF-1α in tumor tissues and adjacent healthy tissues as well as serum collected from both gastric cancer patients and normal healthy controls was detected by qRT-PCR. Survival analysis was performed using Kaplan–Meier method. HIF-1α siRNA silencing cell lines were established. Effects of HIF-1α siRNA silencing as well as PI3K activator sc3036 on proliferation, migration, and invasion of gastric cancer cells were detected by Cell counting kit (CCK-8) assay, and Transwell migration and invasion assay. Effects of HIF-1α siRNA silencing on AKT and VEGF were detected by Western blot. Expression of HIF-1α was significantly down-regulated in tumor tissues than in adjacent healthy tissues in most gastric cancer patients. Serum levels of HIF-1α were also higher in gastric cancer patients than in normal healthy people. Serum HIF-1α showed promising diagnostic and prognostic values for gastric cancer. HIF-1α siRNA silencing inhibited the proliferation, migration, and invasion of gastric cancer cells, while PI3K activator sc3036 treatment reduced those inhibitory effects. Down-regulation of HIF-1α can inhibit the proliferation, migration, and invasion of gastric cancer possibly by inhibiting PI3K/AKT pathway and VEGF expression.


Sign in / Sign up

Export Citation Format

Share Document